Indaptus Therapeutics (INDP) refreshes board with two independents as one resigns
Filing Impact
Filing Sentiment
Form Type
8-K/A
Rhea-AI Filing Summary
Indaptus Therapeutics, Inc. filed an amended current report to update a director’s legal name to Johnny Fox Arrowsmith, previously disclosed as Yí Zhang. The amendment also restates recent board changes.
On April 17, 2026, the board appointed Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors, effective April 22, 2026. Both entered into independent director and indemnification agreements. Each will receive an annual cash retainer of $30,000, payable quarterly, plus reimbursement of reasonable expenses. The board determined both are independent under Nasdaq listing standards.
The board is divided into three classes. Mr. Ruan and Dr. Arrowsmith were appointed as Class II directors with terms expiring at the 2026 annual stockholders’ meeting. Junyi Dai and Qinglai Lu serve as Class III directors with terms expiring at the 2027 annual meeting.
Mr. Ruan was named to the audit committee and qualifies as an “audit committee financial expert.” Dr. Arrowsmith joined the nominating committee. The company states there are no family relationships or related-party transactions requiring disclosure for either director.
On April 22, 2026, director Matthew McMurdo resigned from the board. The company reports his resignation did not result from any disagreement regarding operations, policies, or practices.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Annual director retainer: $30,000
Age of Tim Ruan: 40 years
Age of Johnny Fox Arrowsmith: 48 years
+2 more
5 metrics
Annual director retainer
$30,000
Cash retainer per independent director, payable quarterly
Age of Tim Ruan
40 years
Independent director appointed effective April 22, 2026
Age of Johnny Fox Arrowsmith
48 years
Independent director appointed effective April 22, 2026
Class II term end
2026 annual meeting
Term for Class II directors Ruan and Arrowsmith
Class III term end
2027 annual meeting
Term for Class III directors Junyi Dai and Qinglai Lu
Key Terms
independent directors, indemnification agreements, audit committee financial expert, staggered three-year terms, +1 more
5 terms
independent directors financial
"appointed Mr. Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors of the Board"
Members of a company’s board who do not have significant business, family, or financial ties to the company and are not part of its management; they are chosen to provide impartial oversight of strategy, financial reporting, executive pay and risk. They matter to investors because independent directors act like an objective referee, helping ensure decisions favor shareholders’ long-term interests rather than insiders, which can strengthen trust and reduce the chance of mismanagement or conflicts of interest.
indemnification agreements financial
"the Company entered into independent director agreements (the “Director Agreements”) and indemnification agreements"
Indemnification agreements are contracts in which one party agrees to pay for losses, legal costs, or damages another party might face — like a friend promising to cover repair bills if their dog breaks your window. For investors, these agreements matter because they determine who ultimately bears financial and legal risk, affecting a company’s potential liabilities, cash flow needs, and the willingness of executives or partners to take on roles or deals.
audit committee financial expert financial
"The Board has determined that Mr. Ruan qualifies as an “audit committee financial expert”"
A person on a company’s board who has deep knowledge of accounting, financial reporting and auditing, able to understand and question the books, controls and audit work like a trained mechanic inspecting an engine. Investors care because that expertise helps spot errors, weaknesses or misleading statements early, improving the likelihood that financial reports are accurate and reducing the risk of surprises that can hurt a company’s value.
staggered three-year terms financial
"The Board is divided into three classes of directors, with each class serving staggered three-year terms"
emerging growth company financial
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What change did Indaptus Therapeutics (INDP) make in this 8-K/A amendment?
Indaptus Therapeutics updated a director’s legal name to Johnny Fox Arrowsmith, previously identified as Yí Zhang. The amendment clarifies his current legal name while confirming he still uses “Yi Zhang” professionally, without altering any other disclosures from the original current report.
Who were appointed as new independent directors at Indaptus Therapeutics (INDP)?
Indaptus appointed Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors, effective April 22, 2026. Ruan is a seasoned financial executive and current CFO of Ocumension Therapeutics, while Arrowsmith is an intellectual property and life sciences expert and partner at law firm JunHe.
How are the new Indaptus (INDP) directors compensated for board service?
Each new independent director receives a $30,000 annual cash retainer, payable quarterly, plus reimbursement of reasonable out-of-pocket expenses related to board service. They also entered into standard independent director and indemnification agreements providing protection to the fullest extent permitted under Delaware law.
What board committee roles did the new Indaptus Therapeutics (INDP) directors assume?
Tim Ruan joined the Audit Committee and was designated an “audit committee financial expert” under SEC rules. Dr. Johnny Fox Arrowsmith joined the Nominating Committee. These assignments align Ruan’s capital markets experience and Arrowsmith’s governance and legal background with key oversight responsibilities.
Which director resigned from the Indaptus Therapeutics (INDP) board and why?
Director Matthew McMurdo resigned from the Indaptus board on April 22, 2026. The company states his resignation did not result from any disagreement with Indaptus regarding its operations, policies, or practices, indicating a routine departure rather than one driven by a disclosed dispute.
How is the Indaptus Therapeutics (INDP) board of directors structured by class terms?
The Indaptus board is divided into three classes serving staggered three-year terms. Tim Ruan and Dr. Johnny Fox Arrowsmith are Class II directors with terms expiring at the 2026 annual meeting, while Junyi Dai and Qinglai Lu are Class III directors with terms ending at the 2027 annual meeting.